DiaSorin (OTCMKTS:DSRLF) Stock Rating Lowered by Zacks Research

DiaSorin (OTCMKTS:DSRLF) was downgraded by research analysts at Zacks Research from a “hold” rating to a “strong sell” rating in a report released on Thursday,Zacks.com reports.

DSRLF has been the subject of a number of other reports. UBS Group cut DiaSorin from a “buy” rating to a “neutral” rating in a report on Thursday, April 9th. Deutsche Bank Aktiengesellschaft restated a “sell” rating on shares of DiaSorin in a research report on Tuesday. BNP Paribas Exane cut shares of DiaSorin from a “neutral” rating to an “underperform” rating in a research report on Tuesday, July 7th. Finally, Piper Sandler initiated coverage on shares of DiaSorin in a research note on Thursday, June 11th. They set a “neutral” rating on the stock. Two research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and three have given a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Reduce”.

DiaSorin Trading Up 5.6%

Shares of DiaSorin stock opened at $85.56 on Thursday. DiaSorin has a 1 year low of $66.50 and a 1 year high of $100.00. The company has a 50 day simple moving average of $79.59 and a two-hundred day simple moving average of $76.58.

About DiaSorin

DiaSorin S.p.A. is an Italy?based global biotechnology company specializing in the development, manufacture and marketing of in vitro diagnostic products. Headquartered in Saluggia, DiaSorin serves clinical laboratories, hospitals and physician offices with a broad portfolio of immunodiagnostic assays and molecular diagnostic tests. The company’s shares trade on the Milan Stock Exchange and are available in the United States as over?the?counter (OTC) securities under the symbol DSRLF.

At the core of DiaSorin’s business are immunodiagnostic systems that measure antibodies, antigens and hormones in human samples.